

## Complete Summary

---

### TITLE

Menopause and hormone therapy (HT): collaborative decision-making and management: the percentage of women in menopause who have had a bone mineral density (BMD) measurement after cessation of HT.

### SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2005 Aug. 64 p. [176 references]

## Measure Domain

### PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

### SECONDARY MEASURE DOMAIN

Does not apply to this measure

## Brief Abstract

### DESCRIPTION

This measure is used to assess the percentage of women in menopause who have had a bone mineral density (BMD) measurement after cessation of hormone therapy (HT).

### RATIONALE

The priority aim addressed by this measure is to increase the percentage of women with appropriate follow-up to cessation of hormone therapy (HT).

### PRIMARY CLINICAL COMPONENT

Menopause; hormone therapy (HT); bone mineral density (BMD) measurement

## DENOMINATOR DESCRIPTION

Total number of women in the medical group's practice in menopause who have discontinued hormone therapy (HT) (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

## NUMERATOR DESCRIPTION

Number of women in menopause receiving a bone mineral density (BMD) measurement after cessation of hormone therapy (HT) (see the related "Numerator Inclusions/Exclusions" field in the Complete Summary)

## Evidence Supporting the Measure

### EVIDENCE SUPPORTING THE CRITERION OF QUALITY

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

### NATIONAL GUIDELINE CLEARINGHOUSE LINK

- [Menopause and hormone therapy \(HT\): collaborative decision-making and management.](#)

## Evidence Supporting Need for the Measure

### NEED FOR THE MEASURE

Unspecified

## State of Use of the Measure

### STATE OF USE

Current routine use

### CURRENT USE

Internal quality improvement

## Application of Measure in its Current Use

### CARE SETTING

Physician Group Practices/Clinics

### PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

#### LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Group Clinical Practices

#### TARGET POPULATION AGE

Unspecified

#### TARGET POPULATION GENDER

Female (only)

#### STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

### Characteristics of the Primary Clinical Component

#### INCIDENCE/PREVALENCE

More women than ever before will be entering menopause as the "baby boomer" generation ages. By the year 2020, the number of perimenopausal women will almost double, to 40 million.

#### EVIDENCE FOR INCIDENCE/PREVALENCE

Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2005 Aug. 64 p. [176 references]

#### ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

#### BURDEN OF ILLNESS

Unspecified

#### UTILIZATION

Unspecified

#### COSTS

Unspecified

## Institute of Medicine National Healthcare Quality Report Categories

### IOM CARE NEED

Living with Illness

### IOM DOMAIN

Effectiveness

## Data Collection for the Measure

### CASE FINDING

Users of care only

### DESCRIPTION OF CASE FINDING

Women who are in menopause and have discontinued hormone therapy (HT)

Select a randomized sample of the eligible population for data collection. The suggested sample size for each medical group is at least 10 charts each month.

The medical record of each woman is reviewed to determine if the woman is in menopause and had discontinued HT.

The suggested time frame for data collection is a calendar month.

### DENOMINATOR SAMPLING FRAME

Patients associated with provider

### DENOMINATOR INCLUSIONS/EXCLUSIONS

#### Inclusions

Total number of women in the medical group's practice\* in menopause\*\* who have discontinued hormone therapy (HT)

\*"In the medical group practice" is defined as a woman who has been seen two or more times by the medical group (including office visits and urgent care).

\*\*A woman is diagnosed as having menopause if 1) she has had complete cessation of menses for one year, 2) premature menopause, or 3) if younger than average, or continuation of regular menses, has a positive follicle stimulating hormone (FSH) and/or estradiol lab test. This would correspond to patients with diagnosis codes 627.0 – 627.9.

#### Exclusions

Unspecified

### DENOMINATOR (INDEX) EVENT

Clinical Condition  
Therapeutic Intervention

#### DENOMINATOR TIME WINDOW

Time window follows index event

#### NUMERATOR INCLUSIONS/EXCLUSIONS

##### Inclusions

Number of women in menopause receiving a bone mineral density (BMD) measurement\* after cessation of hormone therapy (HT)

\*This would correspond to patients with Current Procedure Terminology (CPT) codes 80418, 80426, and/or 82670.

##### Exclusions

Unspecified

#### NUMERATOR TIME WINDOW

Episode of care

#### DATA SOURCE

Administrative data

Medical record

#### LEVEL OF DETERMINATION OF QUALITY

Individual Case

#### PRE-EXISTING INSTRUMENT USED

Unspecified

### Computation of the Measure

#### SCORING

Rate

#### INTERPRETATION OF SCORE

Better quality is associated with a higher score

#### ALLOWANCE FOR PATIENT FACTORS

Unspecified

## STANDARD OF COMPARISON

Internal time comparison

## Evaluation of Measure Properties

## EXTENT OF MEASURE TESTING

Unspecified

## Identifying Information

## ORIGINAL TITLE

The percentage of women in menopause who have had a BMD measurement after cessation of HT.

## MEASURE COLLECTION

[Menopause and Hormone Therapy \(HT\): Collaborative Decision-Making and Management Measures](#)

## DEVELOPER

Institute for Clinical Systems Improvement

## ADAPTATION

Measure was not adapted from another source.

## RELEASE DATE

2004 Oct

## REVISION DATE

2005 Aug

## MEASURE STATUS

This is the current release of the measure.

This measure updates a previous version: Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2004 Oct. 57 p.

## SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2005 Aug. 64 p. [176 references]

## MEASURE AVAILABILITY

The individual measure, "The percentage of women in menopause who have had a BMD measurement after cessation of HT," is published in "Health Care Guideline: Menopause and Hormone Therapy (HT): Collaborative Decision-Making and Management." This document is available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](#).

For more information, contact ICSI at, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; phone: 952-814-7060; fax: 952-858-9675; Web site: [www.icsi.org](http://www.icsi.org); e-mail: [icsi.info@icsi.org](mailto:icsi.info@icsi.org).

## NQMC STATUS

This NQMC summary was completed by ECRI on January 19, 2005. This NQMC summary was updated by ECRI on October 25, 2005.

## COPYRIGHT STATEMENT

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.

© 2006 National Quality Measures Clearinghouse

Date Modified: 9/25/2006

